Zevra Therapeutics (ZVRA) legal chief granted RSUs, options and sells stock
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Zevra Therapeutics insider Rahsaan W. Thompson, the Chief Legal & Compliance Officer and Secretary, reported multiple equity transactions in late January 2026. On January 29, he received 37,500 restricted stock units, which start vesting on January 29, 2027 in yearly installments, and a stock option for 75,000 shares at $8.86 per share that vests over four years and expires in 2036.
On January 30, one third of a prior restricted stock unit grant, or 11,333 units, vested and converted into common shares. The same day, he sold 4,080 common shares at a weighted average price of $8.8259 under a pre-arranged Rule 10b5-1 trading plan adopted on March 27, 2025, leaving him with 49,919 common shares held directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
Net Seller: 4,080 shares ($36,010)
Net Sell
5 txns
Insider
Thompson Rahsaan
Role
Chief Legal & Compliance
Sold
4,080 shs ($36K)
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Exercise | Restricted Stock Unit | 11,333 | $0.00 | -- |
| Exercise | Common Stock | 11,333 | $0.00 | -- |
| Sale | Common Stock | 4,080 | $8.8259 | $36K |
| Grant/Award | Restricted Stock Unit | 37,500 | $0.00 | -- |
| Grant/Award | Stock Option (right to buy) | 75,000 | $0.00 | -- |
Holdings After Transaction:
Restricted Stock Unit — 22,667 shares (Direct);
Common Stock — 53,999 shares (Direct);
Stock Option (right to buy) — 75,000 shares (Direct)
Footnotes (1)
- Each restricted stock unit represents a contingent right to receive one share of the Issuer's common stock. Adoption date of referenced 10b5-1(c) plan is: 3/27/2025. This transaction was executed in multiple trades at prices ranging from $8.58 to $9.04. The price reported reflects the weighted average sale price. The Reporting Person undertakes to provide upon request to the SEC staff, the Issuer or any security holder of the Issuer full information regarding the number of shares and prices at which the transaction was effected. The restricted stock units will vest and settle as to one third of the restricted stock units on January 29, 2027, and the remaining two thirds of the restricted stock units will vest and settle in equal annual installments thereafter, subject in each case to the Reporting Person's continued service through such vesting date. Grant to the Reporting Person of a stock option under the Issuer's Amended and Restated 2014 Equity Incentive Plan. The option will vest and become exercisable in four equal annual installments beginning on the first anniversary of the grant date, subject to the Reporting Person's continued service on such vesting date. One third of the restricted stock units vested and settled on January 30, 2026. The remaining two thirds of the restricted stock units will vest and settle in equal annual installment thereafter, subject in each case to the Reporting Person's continued service through such vesting date.
FAQ
What insider transactions did ZVRA executive Rahsaan Thompson report?
Rahsaan Thompson reported new equity awards and share activity. He received 37,500 restricted stock units and a 75,000-share stock option, had 11,333 restricted stock units vest into common shares, and sold 4,080 common shares in a planned trade at a weighted average price of $8.8259.
Was the ZVRA insider stock sale under a 10b5-1 trading plan?
Yes. The reported sale of 4,080 Zevra Therapeutics common shares was executed under a Rule 10b5-1(c) trading plan. The company states the referenced plan was adopted on March 27, 2025, indicating the sale followed a pre-established trading arrangement.
What new restricted stock units did the ZVRA officer receive in January 2026?
On January 29, 2026, he received 37,500 restricted stock units. One third will vest and settle on January 29, 2027, and the remaining two thirds will vest and settle in equal annual installments thereafter, conditioned on his continued service through each vesting date.
What are the terms of the new ZVRA stock option grant to Rahsaan Thompson?
He received a stock option covering 75,000 shares at an exercise price of $8.86. Granted under the Amended and Restated 2014 Equity Incentive Plan, the option vests in four equal annual installments beginning one year after the grant date and expires on January 28, 2036.